These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 34781853)

  • 1. The Ci3+3 design for dual-agent combination dose-finding clinical trials.
    Yuan S; Zhou T; Lin Y; Ji Y
    J Biopharm Stat; 2021 Nov; 31(6):745-764. PubMed ID: 34781853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trials.
    Shi H; Cao J; Yuan Y; Lin R
    Stat Med; 2021 May; 40(11):2626-2649. PubMed ID: 33650708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2.
    Guo W; Wang SJ; Yang S; Lynn H; Ji Y
    Contemp Clin Trials; 2017 Jul; 58():23-33. PubMed ID: 28458054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian optimization design for finding a maximum tolerated dose combination in phase I clinical trials.
    Takahashi A; Suzuki T
    Int J Biostat; 2021 Apr; 18(1):39-56. PubMed ID: 33818029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian adaptive linearization method for phase I drug combination trials with dimension reduction.
    Pan H; Cheng C; Yuan Y
    Pharm Stat; 2020 Sep; 19(5):561-582. PubMed ID: 32248647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designing and evaluating dose-escalation studies made easy: The MoDEsT web app.
    Pallmann P; Wan F; Mander AP; Wheeler GM; Yap C; Clive S; Hampson LV; Jaki T
    Clin Trials; 2020 Apr; 17(2):147-156. PubMed ID: 31856600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A product of independent beta probabilities dose escalation design for dual-agent phase I trials.
    Mander AP; Sweeting MJ
    Stat Med; 2015 Apr; 34(8):1261-76. PubMed ID: 25630638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
    Guo B; Li Y
    Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Keyboard design for phase I drug-combination trials.
    Pan H; Lin R; Zhou Y; Yuan Y
    Contemp Clin Trials; 2020 May; 92():105972. PubMed ID: 32151751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian optimal interval design for dose finding in drug-combination trials.
    Lin R; Yin G
    Stat Methods Med Res; 2017 Oct; 26(5):2155-2167. PubMed ID: 26178591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian adaptive dose-escalation designs for simultaneously estimating the optimal and maximum safe dose based on safety and efficacy.
    Yeung WY; Reigner B; Beyer U; Diack C; Sabanés Bové D; Palermo G; Jaki T
    Pharm Stat; 2017 Nov; 16(6):396-413. PubMed ID: 28691311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
    Lin R; Yin G
    Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time-to-event model-assisted designs for dose-finding trials with delayed toxicity.
    Lin R; Yuan Y
    Biostatistics; 2020 Oct; 21(4):807-824. PubMed ID: 30984972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A simple Bayesian decision-theoretic design for dose-finding trials.
    Fan SK; Lu Y; Wang YG
    Stat Med; 2012 Dec; 31(28):3719-30. PubMed ID: 22763943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of Bayesian optimal interval (BOIN) design with interval 3+3 (i3+3) design for phase I oncology dose-finding trials.
    Zhou Y; Li R; Yan F; Lee JJ; Yuan Y
    Stat Biopharm Res; 2021; 13(2):147-155. PubMed ID: 34249223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian interval-based oncology dose-finding design with repeated quasi-continuous toxicity model.
    Zhao D; Zhu J; Wang L
    Contemp Clin Trials; 2021 Mar; 102():106265. PubMed ID: 33418097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
    Gerke O; Siedentop H
    Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probability intervals of toxicity and efficacy design for dose-finding clinical trials in oncology.
    Lin X; Ji Y
    Stat Methods Med Res; 2021 Mar; 30(3):843-856. PubMed ID: 33327870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-stage dose expansion cohort (MSDEC) design with Bayesian stopping rule.
    Wang S; Tan M
    J Biopharm Stat; 2022 Jul; 32(4):600-612. PubMed ID: 35699319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Escalation strategies for combination therapy Phase I trials.
    Sweeting MJ; Mander AP
    Pharm Stat; 2012; 11(3):258-66. PubMed ID: 22411472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.